申请人:Merck & Co., Inc.
公开号:US04539332A1
公开(公告)日:1985-09-03
Analogs of 2,5-Diaryl tetrahydrofurans which were substituted or unsubstituted at 3,4-positions were prepared. These compounds are found to have potent and specific PAF (Platelet Activating Factor) antagonistic activities and thereby useful in the treatment of various diseases or disorders mediated by the PAF, for example, inflammation, cardiovascular disorder, asthma, lung edema, adult respiratory distress syndrome, pain, and aggregation of platelets.
制备了取代或未取代3,4位的2,5-二芳基四氢呋喃类似物。发现这些化合物具有强效和特异性的PAF(血小板活化因子)拮抗活性,因此在治疗各种由PAF介导的疾病或疾病方面非常有用,例如炎症、心血管疾病、哮喘、肺水肿、成人呼吸窘迫综合征、疼痛和血小板聚集。